Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Joseph V. Pergolizzi$suffix/text()$suffix/text(), Jo Ann LeQuang, Robert Taylor$suffix/text()$suffix/text(), Michael H. Ossipov, Daniel Colucci & Robert B. Raffa. (2018) Designing safer analgesics: a focus on μ-opioid receptor pathways. Expert Opinion on Drug Discovery 13:10, pages 965-972.
Read now
Read now
Nebojsa Nick Knezevic, Tatiana Tverdohleb, Ivana Knezevic & Kenneth D Candido. (2015) Unique pharmacology of tapentadol for treating acute and chronic pain. Expert Opinion on Drug Metabolism & Toxicology 11:9, pages 1475-1492.
Read now
Read now
Howard S Smith & John F Peppin. (2014) Toward a systematic approach to opioid rotation. Journal of Pain Research 7, pages 589-608.
Read now
Read now
Charles E. Argoff & Ernest A. Kopecky. (2014) Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options. Current Medical Research and Opinion 30:12, pages 2543-2559.
Read now
Read now
Michael J Brennan. (2013) Update on prescription extended-release opioids and appropriate patient selection. Journal of Multidisciplinary Healthcare 6, pages 265-280.
Read now
Read now
Nalini Vadivelu, Yili Huang, Brian Mirante, Michael Jacoby, Ferne R Braveman, Roberta L Hines & Raymond Sinatra. (2013) Patient considerations in the use of tapentadol for moderate to severe pain. Drug, Healthcare and Patient Safety 5, pages 151-159.
Read now
Read now
Articles from other publishers (34)
Zunaira Qureshi, Murtaza Najabat Ali & Minahil Khalid. (2022) An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy. Journal of Diabetes Research 2022, pages 1-19.
Crossref
Crossref
Elijah D. Counterman & Sean D. Lawley. (2021) Designing Drug Regimens that Mitigate Nonadherence. Bulletin of Mathematical Biology 84:1.
Crossref
Crossref
Elijah D. Counterman & Sean D. Lawley. (2021) What should patients do if they miss a dose of medication? A theoretical approach. Journal of Pharmacokinetics and Pharmacodynamics 48:6, pages 873-892.
Crossref
Crossref
Mikala C. Osani, L. Stefan Lohmander & Raveendhara R. Bannuru. (2021) Is There Any Role for Opioids in the Management of Knee and Hip Osteoarthritis? A Systematic Review and Meta‐Analysis. Arthritis Care & Research 73:10, pages 1413-1424.
Crossref
Crossref
Abigail Duvall, Thomas N. Tully, James W. Carpenter, Butch KuKanich, Hugues Beaufrère & Geraldine C. Magnin. (2021) Pilot Study of a Single Dose of Orally Administered Tapentadol Suspension in Hispaniolan Amazon Parrots (Amazona ventralis). Journal of Avian Medicine and Surgery 35:1.
Crossref
Crossref
Torbjørn Rian, Eirik Skogvoll, Janne Hofstad, Lise Høvik, Siri B. Winther, Vigdis Schnell Husby, Jomar Klaksvik, Tarjei Egeberg, Kari Sand, Pål Klepstad & Tina Strømdal Wik. (2021) Tapentadol vs oxycodone for postoperative pain treatment the first 7 days after total knee arthroplasty: a randomized clinical trial. Pain 162:2, pages 396-404.
Crossref
Crossref
Suzanne Nielsen, Rose Crossin, Melissa Middleton, Tina Lam, James Wilson, Debbie Scott, Catherine Martin, Karen Smith & Dan Lubman. (2020) Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Victoria, Australia from 2013 to 2018. Addiction 115:6, pages 1075-1087.
Crossref
Crossref
Xiao-Fang Mao, Muhammad Zaeem Ahsan, Evhy Apryani, Xue-Qi Tang, Meng-Jing Zhao, Xin-Yan Li & Yong-Xiang Wang. (2020) Dual μ-opioid receptor and norepinephrine reuptake mechanisms contribute to dezocine- and tapentadol-induced mechanical antiallodynia in cancer pain. European Journal of Pharmacology 876, pages 173062.
Crossref
Crossref
Amy Peacock, Natasa Gisev, Sonja Memedovic, Briony Larance, Jared Brown, Rose Cairns, Nicholas Buckley, Michael Farrell & Louisa Degenhardt. (2020) Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study. Drug and Alcohol Dependence 206, pages 107697.
Crossref
Crossref
Suzanne Nielsen, Rose Crossin, Melissa Middleton, Catherine Martin, James Wilson, Tina Lam, Debbie Scott, Karen Smith & Dan Lubman. (2019) Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study. BMJ Open 9:5, pages e029170.
Crossref
Crossref
Emanuel Schembri. (2018) Are Opioids Effective in Relieving Neuropathic Pain?. SN Comprehensive Clinical Medicine 1:1, pages 30-46.
Crossref
Crossref
Yingchao Li, Yongjun Wang, Ran Zhang, Cuiru Liu, Yue Wei, Jin Sun, Zhonggui He, Youjun Xu & Tianhong Zhang. (2018) Improving the oral bioavailability of tapentadol via a carbamate prodrug approach: synthesis, bioactivation, and pharmacokinetics. Drug Delivery and Translational Research 8:5, pages 1335-1344.
Crossref
Crossref
Brian A. Baldo. (2018) Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Archives of Toxicology 92:8, pages 2457-2473.
Crossref
Crossref
Joseph V. PergolizziJrJr, Robert TaylorJrJr, Jo Ann LeQuang, Robert B. Raffa & John Bisney. (2018) Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain. Pain and Therapy 7:1, pages 37-57.
Crossref
Crossref
Carmen Abeyaratne, Samanta Lalic, J. Simon Bell & Jenni Ilomäki. (2018) Spontaneously reported adverse drug events related to tapentadol and oxycodone/naloxone in Australia. Therapeutic Advances in Drug Safety 9:4, pages 197-205.
Crossref
Crossref
Amy Peacock, Briony Larance, Michael Farrell, Rose Cairns, Nicholas Buckley & Louisa Degenhardt. (2018) Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol. BMJ Open 8:3, pages e020006.
Crossref
Crossref
Heath B. McAnallyHeath B. McAnally. 2018. Opioid Dependence. Opioid Dependence
73
97
.
Edvina Galiè, Veronica Villani, Irene Terrenato & Andrea Pace. (2017) Tapentadol in neuropathic pain cancer patients: a prospective open label study. Neurological Sciences 38:10, pages 1747-1752.
Crossref
Crossref
Vijay Benade, Ramakrishna Nirogi, Gopinadh Bhyrapuneni, Saivishal Daripelli, Ganesh Ayyanki, Shantaveer Irappanavar, Ranjithkumar Ponnamaneni & Arunkumar Manoharan. (2017) Mechanistic evaluation of tapentadol in reducing the pain perception using in-vivo brain and spinal cord microdialysis in rats. European Journal of Pharmacology 809, pages 224-230.
Crossref
Crossref
Joseph V PergolizziJrJr, Frank Breve, Robert TaylorJrJr, Robert B Raffa, Stephani E Strasburger & Jo Ann LeQuang. (2017) Considering tapentadol as a first-line analgesic: 14 questions. Pain Management 7:4, pages 331-339.
Crossref
Crossref
Juliana Faria, Joana Barbosa, Sandra Leal, Luís Pedro Afonso, João Lobo, Roxana Moreira, Odília Queirós, Félix Carvalho & Ricardo Jorge Dinis-Oliveira. (2017) Effective analgesic doses of tramadol or tapentadol induce brain, lung and heart toxicity in Wistar rats. Toxicology 385, pages 38-47.
Crossref
Crossref
Zengdong Meng, Jing Yu, Michael Acuff, Chong Luo, Sanrong Wang, Lehua Yu & Rongzhong Huang. (2017) Tolerability of Opioid Analgesia for Chronic Pain: A Network Meta-Analysis. Scientific Reports 7:1.
Crossref
Crossref
Liping Zhang, Xiaoyu Yan, Sayori Nobe, Peter Zannikos, Mila Etropolski & Partha Nandy. (2016) Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach. Clinical Drug Investigation 37:3, pages 273-283.
Crossref
Crossref
Catherine Y. Choi. (2016) Chronic pain and opiate management. Disease-a-Month 62:9, pages 334-345.
Crossref
Crossref
Hongki Lee, Virginia De Vito, Mario Giorgi & Hyoin Yun. (2015) Synergistic interaction between tapentadol and flupirtine in the rat orafacial formalin test. European Journal of Pharmacology 762, pages 350-356.
Crossref
Crossref
Emily C. McNaughton, Ryan A. Black, Sarah E. Weber & Stephen F. Butler. (2015) Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse. Pain Medicine 16:1, pages 131-140.
Crossref
Crossref
Stephen F. Butler, Emily C. McNaughton & Ryan A. Black. (2015) Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment. Pain Medicine 16:1, pages 119-130.
Crossref
Crossref
Deepti Jain & Pawan K Basniwal. (2013) ICH guideline practice: application of validated RP-HPLC-DAD method for determination of tapentadol hydrochloride in dosage form. Journal of Analytical Science and Technology 4:1.
Crossref
Crossref
Gina Games & Amber Hutchison. (2013) Tapentadol-ER for the Treatment of Diabetic Peripheral Neuropathy. The Consultant Pharmacist 28:10, pages 672-675.
Crossref
Crossref
Suzanne K. Vosburg, Jermaine D. Jones, Jeanne M. Manubay, Judy B. Ashworth, Douglas Y. Shapiro & Sandra D. Comer. (2013)
A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin
®
(non-TRF) in prescription opioid abusers
. Addiction 108:6, pages 1095-1106.
Crossref
Crossref
Laserina O’Connor. (2013) Understanding individual reactions to opioids in pain management. Nurse Prescribing 11:5, pages 233-239.
Crossref
Crossref
Emily C. McNaughton, Ryan A. Black, Mirella G. Zulueta, Simon H. Budman & Stephen F. Butler. (2012) Measuring online endorsement of prescription opioids abuse: an integrative methodology. Pharmacoepidemiology and Drug Safety 21:10, pages 1081-1092.
Crossref
Crossref
Richard B Silverman, Keith A CandiottiMelvin C Gitlin. (2012) Tapentadol extended-release: a recent addition to our analgesic armamentarium. Pain Management 2:5, pages 451-456.
Crossref
Crossref
Ali Eman, Serbülent Gökhan Beyaz, Hasan Sağlam & Mustafa Emre Gürcü. (2012) Pain Management in Prostate Cancer. Open Journal of Urology 02:03, pages 164-172.
Crossref
Crossref